Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gracell Biotechnologies (GRCL)
NASDAQ:GRCL
RESEARCH TOOLSreports
Holding GRCL?
Track your performance easily
GRCL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.40 - $10.44
Previous Close$10.25
Volume6.42M
Average Volume (3M)1.46M
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$211.42M
Total Debt (Recent Filing)$26.53M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Mar 11, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding67,699,764
10 Day Avg. Volume445,411
30 Day Avg. Volume1,464,495
Standard Deviation0.28
R-Squared0.02
Alpha-0.00054
Financial Highlights & Ratios
Price to Book (P/B)0.29
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio53.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$10.35Price Target Upside0.98% Upside
Rating ConsensusHold
Number of Analyst Covering7
Gracell Biotechnologies News
PremiumPress Releases
Gracell Biotechnologies Acquisition Completed
Ownership Overview
0.00%
Insiders
2.55% Mutual Funds
54.31% Other Institutional Investors
43.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRCL FAQ
What was Gracell Biotechnologies’s price range in the past 12 months?
Gracell Biotechnologies lowest stock price was $1.40 and its highest was $10.44 in the past 12 months.
What is Gracell Biotechnologies’s market cap?
Currently, no data Available
When is Gracell Biotechnologies’s upcoming earnings report date?
Gracell Biotechnologies’s upcoming earnings report date is Mar 11, 2024 which is 261 days ago.
How were Gracell Biotechnologies’s earnings last quarter?
Gracell Biotechnologies released its earnings results on Nov 13, 2023. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.03.
Is Gracell Biotechnologies overvalued?
According to Wall Street analysts Gracell Biotechnologies’s price is currently Undervalued.
Does Gracell Biotechnologies pay dividends?
Gracell Biotechnologies does not currently pay dividends.
What is Gracell Biotechnologies’s EPS estimate?
Gracell Biotechnologies’s EPS estimate is -$0.04.
How many shares outstanding does Gracell Biotechnologies have?
Gracell Biotechnologies has 96,712,360 shares outstanding.
What happened to Gracell Biotechnologies’s price movement after its last earnings report?
Gracell Biotechnologies reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went up 4.318%.
Which hedge fund is a major shareholder of Gracell Biotechnologies?
Among the largest hedge funds holding Gracell Biotechnologies’s share is Baker Bros Advisors LP. It holds Gracell Biotechnologies’s shares valued at 21M.
---
Gracell Biotechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.35 (0.98% Upside)
$10.35 (0.98% Upside)
Blogger Sentiment
Bullish
GRCL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-32.38%
Trailing 12-Months
Asset Growth
-0.19%
Trailing 12-Months
Company Description
Gracell Biotechnologies
Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfil unmet medical needs in the treatment of cancer.
---
GRCL Earnings Call
Q3 2023
0:00 / 0:00
---
GRCL Stock 12 Month Forecast
Average Price Target
$10.35
▲(0.98% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Kura Oncology
―
Nektar Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering GRCL
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+273.35%
reiterated a buy rating a year ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +273.35% per trade.
---